Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2012-04-30 | Mr. Bonney is the President, Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. |
| 2013-04-25 | Mr. Bonney is the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He holds an BA degree from Bates College. |
| 2014-04-30 | Mr. Bonney is the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. |
| 2015-04-20 | Mr. Bonney was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until December, 2014, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of each Fund. Mr. Bonney is also a Director of Alnylam Pharmaceuticals, Inc. and is Chairman of the Board of Trustees of Bates College. He holds a BA degree from Bates College. |
| 2016-04-18 | Mr. Bonney has been a Partner at Third Rock Ventures since 2016 and was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. |
| 2017-04-18 | Mr. Bonney was a Partner at Third Rock Ventures until 2016 and was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. |
| 2018-04-18 | Mr. Bonney is the Chief Executive Officer and Chairman of the Board of Trustees of Kaleido Biosciences and was a Partner at Third Rock Ventures until 2016 and Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. |
| Filing Date | Source Excerpt |
|---|---|
| 2020-03-25 | Michael W. Bonney Director Since: 2019 Age: 61 Board Committees • Audit Committee • Science & Technology Committee ...Michael W. Bonney received $48,413 total compensation in 2019. |
| 2021-03-25 | Michael W. Bonney Director Since: 2019Age: 62 Board Committees • Audit Committee • Science & Technology Committee Other Public Boards • Kaleido Biosciences, Inc. (Chair) • Alnylam Pharmaceuticals (Chair) • Magenta Therapeutics (Chair) Former • Celgene Corporation • Global Blood Therapeutics, Inc. • Sarepta Therapeutics Inc. • Syros Pharmaceuticals Experience • Chair of the Board of Kaleido Biosciences, Inc.(2020-present); Executive Chair of the Board of Kaleido Biosciences, Inc. (2018-2020); Chief Executive Officer and Chairman (2017-2018) • Partner of Third Rock Ventures, LLC (January-July 2016) • Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. until acquired by Merck & Co., Inc. (2003-2014) • Vice President, Sales and Marketing at Biogen, Inc. (1998-2001) • Spent eleven years at Zeneca Pharmaceuticals (1984-1995) • Chair of the Board of Trustees of Bates College (2010–2019) Key Skills and Experience • Public Company CEO / CFO • Healthcare • Financial • Science / Technology / Innovation Other • Director of Gulf of Maine Research Institute • Board of Trustees of the non-profit Rare |
Data sourced from SEC filings. Last updated: 2025-07-01